CareLit Fachartikel

Endlich neue Therapieoptionen beim malignen Melanom

N.N. · DMW - Deutsche Medizinische Wochenschrift · 2014 · Heft 28/29 · S. 1462-1467

Dokument
1052164
CareLit-ID
Jahr
2014
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
DMW - Deutsche Medizinische Wochenschrift
Autor:innen
N.N.
Ausgabe
Heft 28/29 / 2014
Jahrgang 139
Seiten
1462-1467
Erschienen: 2014-07-01 00:00:00
ISSN
0012-0472
DOI
10.1055/s-0034-1370155

Zusammenfassung

Abstract In recent years there has been a fundamental change in the treatment of melanoma. New therapeutic options such as the targeted therapy of BRAF-mutated melanoma and the immunotherapy ipilimumab are available. In about 50 % of melanoma patients a BRAF mutation is found. BRAF inhibitors dabrafenib and vemurafenib show objective response rates of about 60 % with quick responses and relatively good tolerability. However, duration of the response is usually limited to a median of 7 months. Immunotherapy with ipilimumab has significantly lower response rates and may cause severe immune-related adverse events,…

Schlagworte

BRAF malignes Melanom zielgerichtete Therapie Immuntherapien Ipilimumab malignant melanoma targeted therapies immunotherapies DMW - Deutsche Medizinische Wochenschrift